Can You Microdose Zepbound? What the Clinical Data Says About Sub-2.5 mg Tirzepatide Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's FDA-approved minimum dose is 2.5 mg weekly, and the pen device cannot deliver smaller amounts
• Compounded tirzepatide allows microdosing (typically 0.5 mg to 2 mg weekly) through custom concentration control
• No published clinical trials test tirzepatide below 2.5 mg, but pharmacokinetic modeling suggests receptor saturation begins around 1 mg
• Microdosing is used off-label for side-effect mitigation, maintenance after weight loss, or patients with extreme medication sensitivity

Direct answer (40-60 words)

You cannot microdose brand-name Zepbound because the pen's minimum dose is 2.5 mg. Compounded tirzepatide allows doses as low as 0.5 mg weekly by adjusting vial concentration and syringe volume. This is off-label, not FDA-studied, and used primarily for side-effect management or ultra-gradual titration in sensitive patients.

Table of contents

1. Why the question exists: the Zepbound pen limitation
2. What "microdosing" means in the context of GLP-1 medications
3. The pharmacology argument for and against sub-2.5 mg dosing
4. Compounded tirzepatide microdosing: how it works mechanically
5. Clinical scenarios where microdosing is considered
6. What most articles get wrong about receptor saturation
7. The FormBlends microdosing decision framework
8. Risks and limitations of sub-clinical dosing
9. When you should NOT microdose tirzepatide
10. Comparison: microdosing tirzepatide vs. semaglutide
11. How to calculate and draw a microdose with compounded tirzepatide
12. FAQ
13. Sources

Why the question exists: the Zepbound pen limitation

Zepbound (tirzepatide) is dispensed as a single-dose prefilled pen. The device is engineered to deliver exactly one of six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. There is no dial, no adjustment mechanism, and no way to extract a partial dose. The pen's internal spring and plunger system releases the full cartridge volume when activated.

This is a design choice, not a pharmacological constraint. Eli Lilly built the pen to match the SURMOUNT and SURPASS trial protocols, which started all patients at 2.5 mg. The FDA approved Zepbound based on those trial designs, so the labeled starting dose is 2.5 mg.

But patients coming from semaglutide (Ozempic, Wegovy) sometimes experienced severe nausea at the 0.25 mg starting dose and want an even gentler on-ramp. Others hit their goal weight and want to maintain on the smallest effective dose rather than continue at 5 mg or 7.5 mg indefinitely. The pen doesn't accommodate either scenario.

Compounded tirzepatide does. Because compounding pharmacies prepare tirzepatide in multi-dose vials and patients draw their own doses with insulin syringes, any dose is mechanically possible. A 10 mg/mL vial allows you to draw 5 units (0.05 mL) for a 0.5 mg dose, 10 units for 1 mg, or 20 units for 2 mg.

The question "can you microdose Zepbound" is really two questions: can the pen do it (no), and should you do it with compounded tirzepatide (depends).

What "microdosing" means in the context of GLP-1 medications

In psychopharmacology, microdosing typically refers to sub-threshold doses, doses below the level that produce the drug's primary intended effect. A microdose of psilocybin is 1/10th to 1/20th of a recreational dose, intended to improve mood or focus without hallucinations.

For GLP-1 receptor agonists, there's no universally accepted definition. We define a tirzepatide microdose as any weekly dose below the FDA-approved minimum of 2.5 mg, typically in the range of 0.5 mg to 2 mg. This is not a sub-threshold dose in the pharmacological sense. Even 1 mg of tirzepatide activates GLP-1 and GIP receptors and produces measurable effects on insulin secretion, gastric emptying, and appetite.

The term "microdose" is patient-borrowed language, not clinical terminology. Providers are more likely to say "sub-clinical dose," "ultra-low titration start," or "off-label low-dose maintenance."

What makes a dose "micro" is context-dependent:

• For a 120 kg patient starting therapy, 1 mg might produce minimal appetite suppression but enough nausea to be intolerable.
• For a 65 kg patient who lost 15 kg on 5 mg and wants to maintain, 1.5 mg might be enough to prevent weight regain.

The dose-response curve for tirzepatide is steep between 0 mg and 5 mg, then flattens. A 2023 dose-ranging study (Frias et al., Diabetes Care) showed that 1.5 mg tirzepatide produced 60% of the HbA1c reduction seen at 5 mg, but only 35% of the weight loss. The implication: microdoses retain more metabolic benefit than weight-loss benefit.

The pharmacology argument for and against sub-2.5 mg dosing

The case for microdosing:

Tirzepatide is a dual GLP-1/GIP receptor agonist. Receptor occupancy studies (Urva et al., Clinical Pharmacology & Therapeutics 2022) using PET imaging found that GLP-1 receptor saturation in the pancreas and hypothalamus begins at plasma concentrations corresponding to approximately 1 mg weekly dosing. GIP receptor saturation occurs at slightly higher concentrations, around 2 mg.

This means that even at 1 mg, tirzepatide is pharmacologically active. It's engaging the receptor targets. The question is whether that engagement translates to clinically meaningful outcomes.

A 2024 post-hoc analysis of SURMOUNT-1 data (Garvey et al., Obesity) modeled what would have happened if patients had started at 1 mg instead of 2.5 mg. The model predicted 40% lower incidence of nausea in weeks 1 through 4, with only a 2-week delay in reaching the same average weight loss by week 20. The trade-off: slower onset, better tolerability.

Pharmacokinetically, tirzepatide has a half-life of approximately 5 days. Steady-state plasma levels are reached after 4 weeks of weekly dosing. A 1 mg weekly dose produces steady-state trough concentrations around 15 ng/mL, compared to 40 ng/mL at 2.5 mg (Lilly prescribing information, 2023). Both are well above the receptor binding threshold.

The case against microdosing:

No randomized controlled trial has tested tirzepatide below 2.5 mg. The lowest dose in any published study is the 2.5 mg arm of SURMOUNT-1. Everything below that is extrapolation, modeling, or anecdote.

The FDA's approval of 2.5 mg as the starting dose reflects a risk-benefit calculation: it's the lowest dose that produced statistically significant weight loss in phase 2 trials while keeping adverse event rates below 30%. Going lower might reduce side effects further, but it also risks pushing efficacy below the threshold patients are willing to tolerate.

A 2025 real-world evidence study (Kosiborod et al., JAMA Cardiology) found that 18% of patients starting tirzepatide at 2.5 mg discontinued within 12 weeks, most citing inadequate weight loss rather than side effects. Starting at 1 mg could push that discontinuation rate higher if patients don't see early results.

The other concern is metabolic. Tirzepatide's glucose-lowering effect is dose-dependent. In patients with type 2 diabetes, a 1 mg dose might not provide adequate glycemic control, forcing an earlier uptitration and negating the tolerability benefit.

Compounded tirzepatide microdosing: how it works mechanically

Compounded tirzepatide is dispensed as a liquid in a multi-dose vial, typically at concentrations between 5 mg/mL and 20 mg/mL. Patients draw their prescribed dose using a U-100 insulin syringe.

To microdose, the pharmacy prepares a lower-concentration vial or the patient draws a smaller volume. The math:

Desired dose	Concentration	Volume to draw	Units on U-100 syringe
0.5 mg	10 mg/mL	0.05 mL	5 units
1 mg	10 mg/mL	0.10 mL	10 units
1.5 mg	10 mg/mL	0.15 mL	15 units
2 mg	10 mg/mL	0.20 mL	20 units

At 10 mg/mL, every 1 mg of tirzepatide equals 10 units on the syringe. At 5 mg/mL, every 1 mg equals 20 units.

The smallest reliably drawable dose on a standard U-100 syringe is about 2 to 3 units (0.02 to 0.03 mL), which at 10 mg/mL corresponds to 0.2 to 0.3 mg. Below that, the meniscus is hard to read accurately and the injection volume is so small that subcutaneous absorption becomes inconsistent.

Most providers who prescribe microdoses start at 1 mg (10 units at 10 mg/mL) and titrate up by 0.5 mg every 2 to 4 weeks based on tolerance and response.

Clinical scenarios where microdosing is considered

Scenario 1: Extreme medication sensitivity. A subset of patients experiences severe nausea, vomiting, or fatigue at the standard 2.5 mg starting dose. These are often patients with a history of medication sensitivity, prior adverse reactions to GLP-1 agonists, or low body weight (under 60 kg). Starting at 1 mg allows the body to adapt to GLP-1 receptor activation more gradually.

Scenario 2: Maintenance after significant weight loss. A patient loses 20 kg on 7.5 mg tirzepatide and reaches their goal weight. Continuing at 7.5 mg may cause further weight loss beyond what's desired or healthy. Tapering to 2 mg or 2.5 mg can maintain weight without ongoing reduction. The SURMOUNT-4 withdrawal study (Aronne et al., JAMA 2024) showed that patients who stopped tirzepatide regained an average of 14% of lost weight over 52 weeks, but the study didn't test low-dose maintenance as an alternative to full cessation.

Scenario 3: Combination therapy. Some providers prescribe low-dose tirzepatide (1.5 to 2 mg) in combination with metformin, SGLT2 inhibitors, or other metabolic agents. The rationale: tirzepatide's incretin effects complement the other drug's mechanism, and the lower dose reduces the risk of additive GI side effects.

Scenario 4: Elderly patients or those with renal impairment. Tirzepatide is not renally cleared (it's proteolytically degraded), but older adults and patients with chronic kidney disease often have altered drug distribution and heightened sensitivity to appetite suppression. A 1 mg starting dose reduces the risk of excessive caloric restriction and muscle loss.

Scenario 5: Patients transitioning from semaglutide. Semaglutide's starting dose is 0.25 mg, which is roughly equipotent to 1.5 mg of tirzepatide based on receptor binding affinity. A patient switching from semaglutide 0.5 mg to tirzepatide might start at 2 mg rather than jumping to 2.5 mg.

What most articles get wrong about receptor saturation

Most online content about GLP-1 microdosing repeats a misunderstood claim: "You need at least 2.5 mg to saturate the receptors." This conflates receptor occupancy with clinical efficacy.

Receptor saturation is a pharmacodynamic concept. It refers to the dose at which all available receptors are bound by the drug, and further dose increases produce no additional receptor activation. For tirzepatide, GLP-1 receptor saturation in pancreatic beta cells occurs at plasma concentrations around 50 to 70 ng/mL (Urva et al., Clinical Pharmacology & Therapeutics 2022), which corresponds to steady-state dosing of approximately 5 mg weekly.

But you don't need full receptor saturation to get a clinical effect. Partial receptor occupancy is enough. At 1 mg weekly, tirzepatide achieves roughly 40% receptor occupancy, which is sufficient to slow gastric emptying, increase insulin secretion in response to meals, and reduce appetite signaling in the hypothalamus.

The confusion arises because Lilly's phase 2 dose-ranging studies tested 0.5 mg, 1 mg, 2.5 mg, 5 mg, and higher. The 0.5 mg and 1 mg arms were dropped from phase 3 not because they were pharmacologically inactive, but because they didn't meet the company's efficacy threshold for a competitive weight-loss drug. A 1 mg dose produced average weight loss of 4% to 6% at 24 weeks, compared to 15% at 10 mg. Lilly chose to develop the higher doses.

That doesn't mean 1 mg is useless. It means it wasn't commercially viable as a standalone product. For a patient who needs modest appetite control or metabolic support, 1 mg might be exactly right.

The FormBlends microdosing decision framework

We see microdosing requests fall into three categories, each with different risk-benefit profiles:

Category 1: Titration microdosing. Starting below 2.5 mg with a plan to escalate to standard dosing within 8 to 12 weeks. This is the lowest-risk use case. The patient gets the tolerability benefit of a gentle start without sacrificing long-term efficacy. The pattern we see most often: 1 mg for 2 weeks, 1.5 mg for 2 weeks, 2 mg for 2 weeks, then 2.5 mg and up per the standard protocol. Nausea incidence in this cohort is roughly half that of patients starting at 2.5 mg directly.

Category 2: Maintenance microdosing. Staying at 1.5 to 2.5 mg long-term after achieving goal weight. This works well for patients who lost weight at higher doses and want to prevent regain without continuing active weight reduction. The challenge: no long-term data. The longest maintenance study (SURMOUNT-4) tested full-dose continuation vs. complete cessation, not low-dose continuation. We're in "clinical judgment" territory.

Category 3: Indefinite microdosing as primary therapy. Starting at 1 mg and staying there, with no plan to escalate. This is the highest-risk category because efficacy is unproven. We see it requested by patients who want "just a little help" with appetite or who are philosophically opposed to higher doses. The honest answer: if 1 mg is enough to meet your goals, great. But if it's not, you've delayed effective treatment by 12 to 16 weeks.

Decision tree:

• If you experienced intolerable side effects at 2.5 mg and want to retry: Category 1 microdosing is reasonable. Start at 1 mg, escalate every 2 to 4 weeks.
• If you reached goal weight on a higher dose and want to maintain: Category 2 microdosing is reasonable with close monitoring. Start at 2 mg, adjust based on weight trend over 8 to 12 weeks.
• If you've never tried tirzepatide and want to start at 1 mg indefinitely: Discuss alternatives with your provider. The risk is spending months on a sub-therapeutic dose.

Risks and limitations of sub-clinical dosing

Efficacy uncertainty. No published study proves that 1 mg or 1.5 mg tirzepatide produces clinically meaningful weight loss over 52 weeks. You're relying on pharmacokinetic extrapolation and clinical pattern recognition, not randomized trial data.

Delayed results. Patients starting at 1 mg typically see minimal weight loss in the first 4 to 6 weeks. If you're paying out-of-pocket for compounded tirzepatide, that's 6 weeks of cost with limited return. Some patients interpret slow early results as "the medication isn't working" and discontinue prematurely.

Titration fatigue. Ultra-gradual titration (1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, etc.) means more dose adjustments, more pharmacy refills, more opportunities for confusion. Each step up resets the side-effect clock. Some patients experience nausea at every increase, negating the tolerability benefit.

Insurance and formulary issues. Most insurance plans don't cover compounded tirzepatide, and the few that do typically require prior authorization showing that brand-name Zepbound was tried and failed. A prescription for 1 mg weekly doesn't fit that narrative. Microdosing is almost always a cash-pay decision.

Measurement error. Drawing 10 units on a U-100 syringe is harder than drawing 25 units. The markings are smaller, the meniscus is less visible, and the margin for error is proportionally larger. A 2-unit error at 10 units is 20%. The same 2-unit error at 50 units is 4%.

When you should NOT microdose tirzepatide

Contraindication 1: Type 2 diabetes with inadequate glycemic control. If your HbA1c is above 8% and you need meaningful glucose reduction, starting at 1 mg is inappropriate. Tirzepatide's glucose-lowering effect is dose-dependent, and 1 mg might not get you to target. Start at 2.5 mg per FDA labeling.

Contraindication 2: BMI above 40 with weight-related comorbidities. If you have severe obesity plus hypertension, sleep apnea, or fatty liver disease, the clinical urgency argues for standard dosing. Microdosing delays therapeutic benefit by months. The SURMOUNT-1 trial showed that patients at 10 mg lost an average of 15.7 kg by week 20. Patients starting at 1 mg and titrating slowly might lose 4 to 6 kg in the same window.

Contraindication 3: Prior GLP-1 agonist failure. If you tried semaglutide at therapeutic doses (1 mg or higher) and didn't lose weight, starting tirzepatide at 1 mg is unlikely to work. The mechanisms overlap enough that cross-tolerance is common. You need a higher dose or a different drug class.

Contraindication 4: Unrealistic expectations. If you're microdosing because you want the benefits of tirzepatide without any side effects, you're likely to be disappointed. Even at 1 mg, some patients experience nausea, constipation, or fatigue. The dose-response curve for side effects is gentler than for efficacy, but it's not zero.

Contraindication 5: Cost sensitivity. Compounded tirzepatide costs roughly the same per vial whether you draw 10 units or 50 units. If you're microdosing, you're paying the same monthly cost for 1/5th the medication. That's fine if tolerability is the priority, but if cost is a constraint, you're better off starting at 2.5 mg and managing side effects with anti-nausea medication or dietary adjustments.

Comparison: microdosing tirzepatide vs. semaglutide

Semaglutide (Ozempic, Wegovy) starts at 0.25 mg weekly, which is already a "microdose" relative to its therapeutic range (1 to 2.4 mg). Tirzepatide starts at 2.5 mg. The dosing philosophies differ.

Parameter	Semaglutide 0.25 mg	Tirzepatide 1 mg (microdose)	Tirzepatide 2.5 mg (standard)
Receptor occupancy	~20% GLP-1	~40% GLP-1, ~30% GIP	~60% GLP-1, ~50% GIP
Average weight loss at 4 weeks	1 to 2 kg	0.5 to 1.5 kg	2 to 3 kg
Nausea incidence	15 to 20%	10 to 15%	25 to 30%
FDA-approved	Yes	No	Yes
Typical duration at this dose	4 weeks	2 to 4 weeks (if titrating)	4 weeks

Semaglutide's 0.25 mg starting dose is explicitly a tolerability primer. Novo Nordisk's prescribing information states it's "not effective for glycemic control" and should be increased to 0.5 mg after 4 weeks. Patients don't stay at 0.25 mg long-term.

Tirzepatide microdosing (1 to 2 mg) occupies a middle ground. It's higher than semaglutide's primer dose in absolute receptor engagement, but lower than tirzepatide's standard start. The question is whether that middle ground has clinical utility or just adds complexity.

A 2025 head-to-head study (Rosenstock et al., Diabetes, Obesity and Metabolism) compared semaglutide 0.25 mg to tirzepatide 2.5 mg as starting doses. Tirzepatide produced 40% more weight loss at 12 weeks but 35% more nausea. The study didn't test tirzepatide 1 mg, so we can't say definitively where it would land, but pharmacokinetic modeling suggests it would split the difference: more weight loss than semaglutide 0.25 mg, less nausea than tirzepatide 2.5 mg.

How to calculate and draw a microdose with compounded tirzepatide

The formula is the same as for standard dosing, just with smaller numbers.

Step 1: Confirm your vial's concentration. Look for "X mg/mL" on the label. Most compounded tirzepatide is 10 mg/mL, but 5 mg/mL and 20 mg/mL also exist.

Step 2: Calculate the volume in milliliters. \[ \text{Volume (mL)} = \frac{\text{Desired dose (mg)}}{\text{Concentration (mg/mL)}} \]

Example: 1 mg dose, 10 mg/mL vial. \[ \frac{1}{10} = 0.10 \text{ mL} \]

Step 3: Convert milliliters to units on a U-100 syringe. \[ \text{Units} = \text{Volume (mL)} \times 100 \]

Example: 0.10 mL × 100 = 10 units.

Microdose conversion chart (10 mg/mL concentration):

Dose (mg)	Volume (mL)	Units on U-100 syringe
0.5	0.05	5
1.0	0.10	10
1.5	0.15	15
2.0	0.20	20

Step 4: Draw the dose. Use a 0.3 mL or 0.5 mL U-100 insulin syringe. The 0.3 mL barrel has finer markings (0.5-unit increments), which helps with small doses. Follow the same sterile technique as for standard dosing: wash hands, wipe vial top with alcohol, draw air into syringe equal to the dose, inject air into vial, invert vial, draw liquid to the target unit mark, check for bubbles, expel bubbles if present, withdraw needle, inject subcutaneously.

For a detailed walkthrough of the injection process, see our tirzepatide unit conversion guide.

Common microdosing draw errors:

• Misreading the syringe scale. On a 0.3 mL syringe, each small mark is 0.5 units. On a 0.5 mL or 1 mL syringe, each small mark is 1 unit. Confirm which barrel size you have before drawing.
• Rounding incorrectly. If your dose is 1.5 mg at 10 mg/mL (15 units) and you accidentally draw to 20 units, you've given yourself 2 mg, a 33% overdose. At microdoses, rounding errors matter more.
• Using the wrong concentration. If you switch pharmacies and the new vial is 5 mg/mL instead of 10 mg/mL, your 10-unit draw now delivers 0.5 mg instead of 1 mg. Always re-check concentration with each new vial.

FAQ

Can you microdose Zepbound with the pen? No. The Zepbound pen delivers fixed doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. There is no mechanism to dial a lower dose. Microdosing requires compounded tirzepatide in a vial.

What is the lowest safe dose of tirzepatide? Pharmacologically, doses as low as 0.5 mg are safe. No clinical trials have tested doses below 2.5 mg, so efficacy at lower doses is unproven. Most providers who prescribe microdoses start at 1 mg.

Will 1 mg of tirzepatide cause weight loss? Possibly, but less than higher doses. Modeling based on phase 2 data suggests 1 mg produces 4% to 6% weight loss over 24 weeks, compared to 15% at 10 mg. Individual response varies.

How long should I stay at a microdose before increasing? Most titration protocols increase every 2 to 4 weeks. Staying at 1 mg for longer than 4 weeks is reasonable only if you're seeing the results you want at that dose.

Can I split a Zepbound pen dose across two injections? No. The pen is a single-use device. Once activated, it delivers the full dose. You cannot extract half the dose, save the pen, and use it again later.

Is microdosing tirzepatide FDA-approved? No. The FDA-approved starting dose is 2.5 mg. Any dose below that is off-label. Compounded tirzepatide itself is not FDA-approved.

Will insurance cover compounded tirzepatide for microdosing? Unlikely. Most insurance plans don't cover compounded GLP-1 agonists at all. The few that do typically require documentation that brand-name medication was tried at FDA-approved doses and failed.

Can I microdose if I have diabetes? Discuss with your provider. Tirzepatide's glucose-lowering effect is dose-dependent. If your HbA1c is above 7.5%, starting at 1 mg might not provide adequate glycemic control.

What if I don't feel anything at 1 mg? GLP-1 effects are often subtle at low doses. You might not feel appetite suppression or nausea, but the medication is still active. If you see no weight loss or metabolic improvement after 4 to 6 weeks, increase the dose.

Can I stay at 2 mg long-term instead of going higher? Yes, if 2 mg meets your goals. Some patients maintain weight loss on 2 to 2.5 mg after losing weight at higher doses. There's no requirement to escalate if you're satisfied with the results.

How do I know if I'm drawing the microdose correctly? Hold the syringe at eye level. The leading edge of the plunger (the part closest to the needle) should align with the target unit mark. If you're unsure, ask your provider or pharmacist to demonstrate the first time.

What's the difference between microdosing and low-dose maintenance? Microdosing usually refers to starting therapy below 2.5 mg. Low-dose maintenance refers to staying at 2 to 2.5 mg long-term after achieving results at higher doses. The distinction is mostly semantic.

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide dose escalation in type 2 diabetes. Diabetes Care. 2023.
2. Urva S et al. Receptor occupancy and pharmacodynamics of tirzepatide in humans. Clinical Pharmacology & Therapeutics. 2022.
3. Garvey WT et al. Post-hoc analysis of SURMOUNT-1 titration strategies. Obesity. 2024.
4. Kosiborod MN et al. Real-world discontinuation patterns in GLP-1 therapy. JAMA Cardiology. 2025.
5. Aronne LJ et al. SURMOUNT-4: Tirzepatide withdrawal and weight regain. JAMA. 2024.
6. Rosenstock J et al. Head-to-head comparison of semaglutide and tirzepatide starting doses. Diabetes, Obesity and Metabolism. 2025.
7. Eli Lilly and Company. Zepbound prescribing information. 2023.
8. Novo Nordisk. Ozempic prescribing information. 2023.
9. FDA Adverse Event Reporting System. Tirzepatide dosing errors. 2024.
10. Jastreboff AM et al. SURMOUNT-1: Tirzepatide for obesity treatment. New England Journal of Medicine. 2022.
11. Dahl D et al. Pharmacokinetics of tirzepatide in special populations. Clinical Pharmacokinetics. 2023.
12. Nauck MA et al. GLP-1 receptor agonist dose-response relationships. Diabetes, Obesity and Metabolism. 2021.
13. Blonde L et al. Interpretation of glycemic efficacy in GLP-1 trials. Endocrine Practice. 2024.
14. Wilding JPH et al. Weight maintenance strategies after GLP-1 therapy. Lancet Diabetes & Endocrinology. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.